Indegene Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Growth concentrated outside the core: Revenue grew 4.9% QoQ and 9.6% FY25, driven by customers outside the Top 20, while the Top 20 grew only 2% YoY after two large accounts dragged overall growth by roughly 6%.
• Margins slipped on investment and mix: FY25 EBITDA margin fell 90 bps to 19.8%, split almost equally between a higher on-site employee mix and increased non-employee technology costs tied to GenAI platform development.
• Two problem customers are the story: One has stabilized and should resume growth; the other, previously thought stable, will see further volume reductions. Together they explain the Top 10 revenue decline, and management says the worst is behind them.
• Large-deal pipeline is real but unbooked: One \$5 mn+ ACV deal with a Top 10 EU pharma and three mid-tier deals are expected to contribute later in FY26, while costs for one large deal are already being incurred ahead of closure.
• What to watch next quarter: Whether the two headwind customers behave as forecast, closure of the large deal where costs are already running, and any sign that the enterprise commercial segment’s low-single-digit growth is reversing.

The Two-Customer Problem

• Magnitude of the hit: Two customers in the Top 10 drove a significant decline that impacted overall growth by roughly 6%. One changed operating methodologies, causing broad leakage that has since been corrected. The other faced internal pressures: declining revenues, margin compression, and major revenue products falling off a cliff.
• Diverging trajectories: The first customer has stabilized and is expected to start growing this year. The second, which management had believed had stabilized, will see some further reductions in volumes. The decline is now behind them; quarter-on-quarter contribution of the top 5 customers showed a marginal increase from 56.3% to 56.4%.
• Largest customer renewal: The largest customer’s renewal, due in March, involves reconfiguration of the on-site/offshore mix in the medical business. This will result in lower value and realization, with roughly ₹0.1 crore revenue impact each quarter for the rest of 2025 starting toward the end of Q1, but no or very low impact on margins.
• Top 20 stagnation: Top 20 customers grew only 2% YoY. While there was good traction with many key accounts, negative events and impacts in some accounts shared through the year held back the aggregate number.

Manish Gupta: "The biggest impact, which a company like us or for the industry is really not these tariffs and stuff like that, right? It's going to be the drug pricing, which we have alluded to. And we believe that is going to continue to be under pressure over time in a secular way."

Margin Walk

• Q4 sequential decline: EBITDA margin dropped 60 bps QoQ, driven by a higher wage bill from seasonal trends in US vacation accrual and payroll taxes, plus midyear and off-cycle increments for a subset of employees. PAT margin improved 30 bps on favorable deferred tax adjustments in the US.
• FY25 full-year compression: EBITDA margin fell 90 bps to 19.8%. The drop split almost equally between a higher on-site employee mix and increased non-employee expenses related to technology, including infrastructure, tokens, and other costs of GenAI platforms used in IP development.
• PAT margin improved: FY25 PAT margin rose 130 bps to 14.3%, driven by a reduction in finance and interest costs and growth in interest income.
• Segment-level stability: Profitability for both large segments (enterprise commercial and enterprise medical) is fairly stable when viewed at the customer engagement level rather than the project level. New engagements may start with lower margins due to a higher on-site mix, then ramp up over time.
• Omnichannel margin recovery: Omnichannel activation margin increased to 13.2% from 8% last quarter, helped by top-line growth, deeper engagements, and longer-term projects that allow better planning and resource utilization. Management expects these drivers to sustain.
• Pre-revenue costs running: For one of the larger deals in the pipeline, Indegene has already started incurring costs, which had a very small impact in Q4 and may continue to impact in the near future until the engagement goes live and revenue starts.

Enterprise Commercial: The Slowdown

• Growth decelerated to low single digits: The slowdown was primarily due to the impact of two large customers in that segment. Management expects growth to come back but declined to call out specific numbers.
• Geographic mix shift: North America revenue share increased to 71.9% from 69.3% in Q3, driven by consolidation at a US-headquartered customer. An enterprise relationship that started in Europe expanded to multi-geographical coverage including the US during a renewal in January 2025.
• No significant Europe vs. US divergence: The largest market continues to be the US, typically accounting for 50%+ of revenues irrespective of where customers are headquartered. Management sees no significant difference between European and US-headquartered customers.

Enterprise Medical: The Growth Engine

• Trilogy acquisition driving wins: The Trilogy acquisition created a robust joint solution in medical writing and submission capabilities, combined with Indegene’s operational scale, processes, and technology. Post-acquisition, the company has won ₹0.2 crore-plus ACV multiyear engagements by going to market in an integrated way.
• Growth breadth: Growth is consistent both in top-20 globally ranked pharma companies and beyond, with traction on both sides including mid-tier companies.
• Domain talent requirement: Domain specialization is required across all segments, with a marginally higher impact if enterprise medical grows faster than the rest of the business, which happened in FY25. Around 21% to 24% of employees would continue to be the domain layer, slightly varied between business segments.

AI, Technology & the Cortex Platform

• Cortex GenAI platform launched: A platform that contextualizes GenAI for the life sciences industry by bringing 26 years of operational experience codified to train AI models. It incorporates agentic workflows and a platform approach to GenAI development. Domain and business process experts are currently training GenAI agents in Cortex, and GenAI agents are being incorporated into existing solutions after testing and validation. GenAI-first products are also being built in the commercial and medical space.
• Technology investment steady: Investment in the office of the CTO for internal IP development and non-billable R&D continues to be a focus area, consistently in the vicinity of 2% of revenue (1.7%-1.8% trending toward 2%), not materially different from the plan going forward.
• GenAI revenue not broken out: Management declined to separate GenAI revenue, arguing that technology has always been a core differentiator and breaking it out "might believe is not a great idea." They acknowledged positive client reactions and multiple conversations but said there are no big closures behind this right now.
• FDA cuts as AI opportunity: In the medium term, clients may require guidance on adjusting strategies in the new regulatory environment and will likely need enhanced bandwidth to counterbalance FDA reductions. Management sees an opportunity to use AI solutions and technology to bridge gaps, as pharma companies will need to submit more comprehensive data cost-effectively.

Manish Gupta: "I would say that we are not going to, unlike other companies, try to break this up because one of our propositions from very early on has been that we bring technology as a big differentiator to deliver superior outcomes, right?"

M&A and Capital Allocation

• MJL Communications Group acquired: A UK-based digital life sciences agency, acquired on a debt-free cash-free basis for an amount not exceeding GBP 0.34 crore including earn-outs, effective end of March 2025. The acquisition strengthens creative presence and capabilities in the UK. The question about its revenue contribution to FY26 and FY27 was cut off by the moderator.
• Cult integration progressing: The combined offering, bringing together Indegene’s medical technology, analytics, and global operations with Cult’s creative capabilities, has already produced customer successes and pilots. Management expects this to translate into increasing revenues this year and beyond.
• Dividend initiated: The board approved a 100% dividend, approximately ₹48 crores (~12% of PAT, ~2.9% of cash), subject to members’ consent at the AGM. Management framed it as good practice and rigor for a young publicly listed company with a long track record of profitable growth.
• M&A pipeline: Management believes the market has been tough over the last few years on the M&A side but expects opportunities to start emerging, and the current macro environment will be conducive for finding the right deals. They will continue to pursue tuck-in acquisitions to enhance, deepen, and broaden capabilities.

Manish Gupta: "As a prudent company with a very long track record of profitable growth, we believe it is a good practice and rigor to start issuing some dividends even as a young publicly listed company."

Guidance & Commitments

Key Metrics